Skip to main content

Table 1 Demographic and clinical characteristics of the MS cohort included in the study

From: Association between multiple sclerosis, cancer risk, and immunosuppressant treatment: a cohort study

Variable

Exposed to IS

Others

Sex (W/M)

531 (336/195)

531 (359/172)

Mean age at onset (years +/− SD)

29 (10)

30 (10)

Mean age at treatment start (years +/− SD)

29.4 (9.9)

40 (13.5)

Mean disease duration (SD)

19 (9)

20 (10)

Mean Follow-up (years +/− SD) for the whole cohort

9 (5)

10 (6)

Mean Follow-up (years +/− SD) for the MX group

8 (5)

_

Mean Follow-up (years +/− SD) for the CP group

5 (5)

_

Mean Follow-up (years +/− SD) for the AZA group

10 (6)

_

Mean treatment duration for the MX group (years)

1

_

Mean treatment duration for the CP group (years)

1

_

Mean treatment duration for the AZA group (years)

4

_